Insys Therapeutics (INSY) Approves $50M Common Stock Buyback
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Insys Therapeutics Announces Stock Repurchase Program
November 5, 2015 6:52 AM ESTPHOENIX, Nov. 05, 2015 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (Nasdaq: INSY) (Insys or the Company) today announced that its Board of Directors has approved the repurchase of up to $50 million of the Company's common stock.
"The Board of Directors and management team believe that shares of Insys stock are an attractive investment opportunity, and we are pleased that Insys strong balance sheet and cash flow enable us to return value to shareholders through a stock repurchase program, said Dr. John Kapoor, Chairman, President and Chief Executive Officer. At the same time, we are continuing to... More
Insys Therapeutics Announces Stock Repurchase Program
November 5, 2015 6:52 AM ESTPHOENIX, Nov. 05, 2015 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (Nasdaq: INSY) (Insys or the Company) today announced that its Board of Directors has approved the repurchase of up to $50 million of the Company's common stock.
"The Board of Directors and management team believe that shares of Insys stock are an attractive investment opportunity, and we are pleased that Insys strong balance sheet and cash flow enable us to return value to shareholders through a stock repurchase program, said Dr. John Kapoor, Chairman, President and Chief Executive Officer. At the same time, we are continuing to... More
Insys Therapeutics Announces Senior Management Changes and Appointments
November 5, 2015 6:51 AM ESTMichael Babich Departs as Insys President and CEO
Dr. John N. Kapoor Appointed President and CEO
Daniel Brennan Appointed Executive Vice President and Chief Operating Officer
PHOENIX, Nov. 05, 2015 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ: INSY) ("Insys" or "the Company") today announced that Michael L. Babich has stepped down as President and Chief Executive Officer of Insys. The Board of Directors has appointed Dr. John N. Kapoor as President and Chief Executive Officer effective November 4, 2015. Dr. Kapoor will... More
